<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00202722</url>
  </required_header>
  <id_info>
    <org_study_id>SSHF812310</org_study_id>
    <nct_id>NCT00202722</nct_id>
  </id_info>
  <brief_title>Remifentanil as Intravenous Patient-controlled Analgesia (IVPCA) During Labour</brief_title>
  <official_title>Remifentanil as Analgesia for Labour Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorlandet Hospital HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sorlandet Hospital HF</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Remifentanil is a ultra short-acting synthetic opioid. It is rapidly metabolized by
      non-specific blood and tissue esterases. We wanted to investigate the efficacy and safety of
      remifentanil used as analgesia during labour. Intravenous patient controlled analgesia
      (ivpca) were used to administer remifentanil. Doses used were 0,15-1,05 mikrogr/kg, with a
      lock-out time of 2 minutes. 41 women were included in the study. Blood-pressure, heartrate,
      SaO2, respiration rate and sedation were recorded every 15.minute. Fetal heart rate was
      recorded for the whole periode of treatment (CTG, STAN). Vaginal contraction pain were
      assessed by the parturients every 15.minute using a Visual Analogue Scale (VAS). Midwives
      also recorded their impression of the parturients pain. The parturients level of sedation
      were recorded by anesthesiologist and midwife every 15.minute. Apgar scores were registered
      at 1, 5 and 10 min after delivery. Umbilical cord blood analysis regarding blood gases and
      concentration of remifentanil were performed. After delivery, both mother and midwife
      evaluated efficacy and safety; Global satisfaction score, if the remifentanil doses were
      sufficient, nausea, vomiting, level of sedation and dizziness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary and secondary outcome measures presented under &quot;results&quot;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">July 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Score, Visual Analogue Scale (VAS) (Mean Maximal Change in Pain)</measure>
    <time_frame>From start with remifentanil treatment until delivery, up to 8 hours.</time_frame>
    <description>Continuous Visual Analogue Scale 0 - 100 millimeters (0=no pain, 100=worst imaginable pain) Registration of pain scores before start and every 15.minute during treatment with remifentanil. Result given is the maximal change in pain score (mean) compared to the baseline value at the given timepoints.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>From start of remifentanil treatment until delivery</time_frame>
    <description>Patient satisfaction with remifentanil pain relief by use of questionnaire answered within 24 hours after delivery. Evalutated by a 5-point scale; 1-very satisfied.......5-very dissatisfied.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Labour Pain</condition>
  <condition>Satisfaction</condition>
  <condition>Adverse Effects</condition>
  <arm_group>
    <arm_group_label>Remifentanil IVPCA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bolus dose steps of 0.15 microgr/kg, with a 2-min lock-out time</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>Intravenous patient controlled analgesia (ivpca) during labour</description>
    <arm_group_label>Remifentanil IVPCA</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy women (ASA I-II), in active labour, one fetus with no suspected pathology,
        expecting normal childbirth, informed consent.

        Exclusion Criteria:

        Failure to obtain informed consent, received opioids within last 8 hours before study
        start, serious side-effects mother and abnormal fetal heart rate.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan H. Rosland, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>part time</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sorlandet sykehus HF</name>
      <address>
        <city>Kristiansand</city>
        <state>Vest-Agder</state>
        <zip>N-4623</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Blair JM, Hill DA, Fee JP. Patient-controlled analgesia for labour using remifentanil: a feasibility study. Br J Anaesth. 2001 Sep;87(3):415-20.</citation>
    <PMID>11517125</PMID>
  </reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <results_first_submitted>March 16, 2010</results_first_submitted>
  <results_first_submitted_qc>May 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 23, 2014</results_first_posted>
  <last_update_submitted>May 22, 2014</last_update_submitted>
  <last_update_submitted_qc>May 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Remifentanil, parenteral opioids, obstetric analgesia, IVPCA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Labor Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruited at arrival to the Labour department</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Effect and Side Effects of Remifentanil</title>
          <description>Analgesic efficacy and side offects of remifentanil during labour and delivery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Women in Labour Given Remifentanil Analgesia</title>
          <description>Administration of remifentanil analgesia startet with cervical dilatation &gt; 4 cm</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" lower_limit="20" upper_limit="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Score, Visual Analogue Scale (VAS) (Mean Maximal Change in Pain)</title>
        <description>Continuous Visual Analogue Scale 0 - 100 millimeters (0=no pain, 100=worst imaginable pain) Registration of pain scores before start and every 15.minute during treatment with remifentanil. Result given is the maximal change in pain score (mean) compared to the baseline value at the given timepoints.</description>
        <time_frame>From start with remifentanil treatment until delivery, up to 8 hours.</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Remifentanil</title>
            <description>Pain scores
Satisfaction</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score, Visual Analogue Scale (VAS) (Mean Maximal Change in Pain)</title>
          <description>Continuous Visual Analogue Scale 0 - 100 millimeters (0=no pain, 100=worst imaginable pain) Registration of pain scores before start and every 15.minute during treatment with remifentanil. Result given is the maximal change in pain score (mean) compared to the baseline value at the given timepoints.</description>
          <population>Per protocol</population>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47" spread="20.2" lower_limit="60" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction</title>
        <description>Patient satisfaction with remifentanil pain relief by use of questionnaire answered within 24 hours after delivery. Evalutated by a 5-point scale; 1-very satisfied.......5-very dissatisfied.</description>
        <time_frame>From start of remifentanil treatment until delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Satisfaction With Remifentanil Analgesia</title>
            <description>Patient satisfaction with remifentanil pain relief by use of questionnaire (within 24-hours after delivery)</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction</title>
          <description>Patient satisfaction with remifentanil pain relief by use of questionnaire answered within 24 hours after delivery. Evalutated by a 5-point scale; 1-very satisfied.......5-very dissatisfied.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of remifentanil analgesia until delivery</time_frame>
      <desc>Continuous monitoring of oxygen saturation</desc>
      <group_list>
        <group group_id="E1">
          <title>Maternal Oxygen Desaturation</title>
          <description>Oxygen saturation lower than 92% during labour and delivery</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oxygen saturation lower than 92%</sub_title>
                <description>Oxygen saturation lower than 92% during labour and delivery, administration of supplemental oxygen</description>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Maternal sedation</sub_title>
                <description>The participants evaluation of sedation level during remifentanil treatment by use of questionnaire within 24 hours after delivery (1=no sedation, 5=very sedated).</description>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tor Tveit</name_or_title>
      <organization>Sorlandet Hospital HF</organization>
      <phone>+4738073608</phone>
      <email>tor.tveit@sshf.no</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

